Addressing Ways to Improve Supply-Chain Security: A Perspective from Pfizer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Addressing Ways to Improve Supply-Chain Security: A Perspective from Pfizer
A Q&A with Brian Johnson, senior director of supply chain security at Pfizer, moderated by Patricia Van Arnum. Part of a special Ingredients issue.

Pharmaceutical Technology
Volume 35, pp. s39-s40

EU efforts

PharmTech: On an industry wide basis, what would you identify as the significant initiatives or programs in place or under consideration to address supply-chain security in Europe?

Johnson: The European Union's Directive on Falsified Medicinal Products will drive a number of supply-chain security enhancements when implemented (2). Some key focus areas include: unit level authentication, tamper evidence , increased regulation of Internet pharmacies, enhanced controls around importation of APIs and excipients, and increased penalties for supply-chain security crimes. There are also a number of trade organizations, consortiums, and coalitions working on various aspects of the problem in Europe, including some of those previously mentioned. I think we are getting closer to a broad recognition that supply-chain security is a global issue for a global market requiring better collaboration and harmonization.

Other international efforts

PharmTech: How do these initiatives in the US and EU connect with activities in Asia (such as in China and India) and other international programs?

Johnson: Both the FDA strategic plan and the EU directive recognize international cooperation among regulators as a key to success in our new global marketplace. The International Conference on Harmonization (ICH), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the World Health Organization's International Medical Products Anti-Counterfeiting Taskforce (WHO–IMPACT) are examples of where this is happening. Law enforcement also collaborates internationally on supply-chain security issues through organizations such as Interpol.

Many of the organizations that I previously mentioned (i.e., Rx–360, PSI, and PSM) also recognize the global nature of the supply-chain security problem and are working to pull international stakeholders together. As an example PSM just created an Indian chapter, and Rx–360, which is already an international consortium, is working hard to increase engagement in Asia.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here